Main Menu

This technology includes three cell lines of dopaminergic neurons derived from human induced pluripotent stem cell (iPSC) line BC1, human iPSG line X1 and human embryonic stem cell (hESC) line H14 to be utilized in neurology research. These cell lines will be used for to study the biology of brain development and may also be used to test different characterization and differentiation assays. The dopaminergic neurons and/or their derivatives may also be used as controls in studies to screen for small molecules to change cell fate and/or to alleviate the phenotypes of various diseases.

This technology involves an innovative method for differentiating neural stem cells (NSCs) into neurons, primarily for use in basic science research and in developing therapies for brain and spinal cord disorders. Existing methods for generating neurons from NSCs typically result in high efficiency but low survival rates, especially when neurons are dissociated and regrown. This new method utilizes Life Technologies StemPro embryonic stem cell serum-free medium, which significantly enhances differentiation efficiency into neurons with minimal cell death.

This technology includes a neural stem cell (NSC) line derived from a Niemann Pick C (NPC) patient, aimed at advancing research and drug development for NPC, an inherited neurodegenerative disorder characterized by the accumulation of cholesterol in neurons. The NSCs, which serve as a crucial intermediate cell type, can be differentiated into any neuronal or glial cell of the brain or spinal cord under appropriate culture conditions. These cells originate from fibroblasts reprogrammed into induced pluripotent stem cells.

This technology includes a number of dimeric RGD peptides which been developed and labeled with various PET isotopes (1BF, 68Ga, and 64Cu) for imaging integrin expression in cancer, inflammation, rheumatoid arthritis, myocardial infarct, stroke and traumatic injury. A number of these peptides have been translated into clinic for diagnosis and therapy response monitoring.

This technology includes p300 KO HEK293T cells using crispr/cas9 mediated gene editing technology to be used for various research applications. We showed that p300 deficient cells have impaired glycolysis and are hypersensitive to glucose depletion-induced cell death. p300 is one of major transcriptional co-activators that regulates gene transcription as a histone acetyltransferase. Recent studies reveal that it functions as "writer" for a variety of lysine acylations, including acetylation, crotonylation, butryrylation, 2- hydroxyisobutyrylation, and succinylation.

This technology includes synthesized demonstrated [1-13C] NAC as a promising novel probe for hyperpolarized 13C MRI methodologies which could provide diagnostic, and evaluation of response to treatment in various cancers and neurological diseases. N-acetyl cysteine (NAC) is a widely used therapeutic and involved to stimulate glutathione synthesis. Glutathione elevates detoxification and works directly as a free radical scavenger. In vivo hyperpolarized NAC was broadly distributed throughout the body.

This technology includes a blood flow imaging method that allows for a higher density of smaller particles to be detected. Current imaging methods that are based on Doppler measurements are limited by the discontinuity in the capillary flow in the space between red blood cells. The core technology is to use a scattering agent to enhance capillary flow or microcirculation. This technology has been tested for optical coherence Doppler tomography, but can be expended to any Doppler based flow imaging techniques such as laser speckle imaging.

This technology includes the development of selective P2Y14R antagonists for the treatment of asthma, sterile inflammation of the kidney, diabetes, and neurodegeneration. The P2Y14 receptor (P2Y14R) is a target for the treatment of inflammatory diseases, including pulmonary and renal conditions. Selective P2Y14R antagonists have demonstrated efficacy in animal models of asthma, pain, diabetes, and acute kidney injury. However, the prototypical antagonist is not optimal for in vivo administration, as it displays a low oral bioavailability.

This technology involves neural stem cells (NSCs) derived from pluripotent stem cells (PSCs) that can differentiate into neurons and glia. The key feature of this technology is the CY2 EEF1A1 GFP iPSC line, which includes a green fluorescent protein (GFP) expressed under the EEF1A1 promoter, leading to its ubiquitous expression in cells. This characteristic makes the NSCs and the neural cells differentiated from this line exhibit green fluorescence. Such cells, when transplanted into animal models like mice and rats, can be easily tracked due to their fluorescence.

The Multichannel Individualized Stimulation Therapy (MIST) device is a multichannel electrical stimulation system that can be used for targeted, individualized electroconvulsive therapy (ECT), especially for treatment-resistant depression (TRD). Millions of individuals suffer from TRD, for which ECT is often the most efficacious and rapidly acting treatment option.